Mangalam Drugs & Organics (NSE:MANGALAM) Cyclically Adjusted PB Ratio: (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
44 GF Score
Price ₹29.86
GF Value ₹62.48
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mangalam Drugs & Organics  (NSE:MANGALAM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Mangalam Drugs & Organics Cyclically Adjusted PB Ratio Related Terms


Mangalam Drugs & Organics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics Cyclically Adjusted PB Ratio Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.64 1.37 1.16 0.84 0.30

Mangalam Drugs & Organics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.78 0.00 0.30 0.00

NSE:MANGALAM vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangalam Drugs & Organics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Mangalam Drugs & Organics's Cyclically Adjusted PB Ratio falls into.


NSE:MANGALAM
44GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Mangalam Drugs & Organics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Mangalam Drugs & Organics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Mangalam Drugs & Organics Quarterly Data

Book Value per Share CPI Adj_Book
201609 46.378 105.961 73.250
201612 0.000 105.196 0.000
201703 54.155 105.196 86.156
201706 0.000 107.109 0.000
201709 60.695 109.021 93.172
201712 0.000 109.404 0.000
201803 65.559 109.786 99.937
201806 0.000 111.317 0.000
201809 67.973 115.142 98.798
201812 0.000 115.142 0.000
201903 60.439 118.202 85.573
201906 0.000 120.880 0.000
201909 61.424 123.175 83.457
201912 0.000 126.235 0.000
202003 65.668 124.705 88.128
202006 0.000 127.000 0.000
202009 77.491 130.118 99.669
202012 0.000 130.889 0.000
202103 82.630 131.771 104.946
202106 0.000 134.084 0.000
202109 88.306 135.847 108.789
202112 0.000 138.161 0.000
202203 95.123 138.822 114.676
202206 0.000 142.347 0.000
202209 98.465 144.661 113.913
202212 0.000 145.763 0.000
202303 96.005 146.865 109.401
202306 0.000 150.280 0.000
202309 83.641 151.492 92.400
202312 0.000 152.924 0.000
202403 85.793 153.035 93.823
202406 0.000 155.789 0.000
202409 93.485 157.882 99.095
202412 0.000 158.323 0.000
202503 94.124 157.552 99.982
202506 0.000 159.755 0.000
202509 80.601 162.289 83.118
202512 0.000 163.281 0.000
202603 65.112 164.272 66.335
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹29.86 is trading 52.2% below its estimated GF Value™ of ₹62.48. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹62.48 vs. price of ₹29.86 (52.2% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
44GF Score

Get the complete analysis for NSE:MANGALAM

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹29.86
Price
₹62.48
GF Value